<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790282</url>
  </required_header>
  <id_info>
    <org_study_id>E2 luteal support in ICSI</org_study_id>
    <nct_id>NCT01790282</nct_id>
  </id_info>
  <brief_title>Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT</brief_title>
  <official_title>Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura Integrated Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura Integrated Fertility Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study if supporting luteal phase of high responder (high egg production or high Estradiol&#xD;
      level) long Gn_Rh agonist protocol ICSI/IVF cycle by combined Estradiol and progesterone&#xD;
      impairs or improves outcome in terms of pregnancy and implanation rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of estradiol (E2) luteal support is still debated after more than a decade of use.&#xD;
      Two recent met analyses (Gelbaya et al 2008) &amp;(Jee et al 2010)( ) has shown that the addition&#xD;
      of E2 to P4 for luteal phase support in IVF/ICSI cycles has no beneficial effect on pregnancy&#xD;
      rates. However they commented that the data in the literature are, limited and heterogeneous,&#xD;
      precluding the extraction of clear and definite conclusions. Previous met analysis ( Pritts&#xD;
      and Atwood 2002 ) and an update (Fatemi et al 2007 ) and subsequent randomized trials (&#xD;
      Ghanem et al 2009 , Var et al 2011 ) reported beneficial effects of adding E2 to luteal P4&#xD;
      support. Recent retrospective studies have shown that high response in terms of excess egg&#xD;
      production ( &gt;15 . ) and or high E2 (Chen et al 2007,Kyrou et al 2009, Sunkara 2011 ) are&#xD;
      detrimental to cycle outcome. This prospective randomized trial aims to study whether adding&#xD;
      E2 to P4 luteal support in high ovarian responders is detrimental to cycle outcome or not&#xD;
&#xD;
      --------------- Gelbaya TA, KyrgiouM, Tsoumpou I, Nardo LG. The use of estradiol for luteal&#xD;
      phase support in in vitro fertilization/intracytoplasmic sperminjec- tion cycles: a&#xD;
      systematic review and meta-analysis. Fertil Steril 2008;90: 2116-25.&#xD;
&#xD;
      Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the&#xD;
      luteal phase of in vitro fertilization cycles: a meta-analysis Fertil Steril. 2010&#xD;
      Feb;93(2):428-36&#xD;
&#xD;
      Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of&#xD;
      randomized trials. Hum Reprod 2002;17:2287-99 Fatemi HM, Popovic-Todorovic B, Papanikolaou E,&#xD;
      Donoso P,Devroey P. An update of luteal phase support in stimulated IVF cycles.Hum Reprod&#xD;
      Update 2007;13:581.&#xD;
&#xD;
        -  Ghanem M E., Ehab E. Sadek, Elboghdady L. A.. Helal A S, Gamal Anas, Eldiasty A Bakre N&#xD;
           I., Houssen M .The effect of luteal phase support protocol on cycle outcome and luteal&#xD;
           phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles:&#xD;
           a randomized clinical trial , Fertility and Sterility 2009 92: 486-493&#xD;
&#xD;
      Var T, Tonguc EA, DoÄŸanay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the&#xD;
      effects of three different luteal phase support protocols on in vitro fertilization outcomes:&#xD;
      a randomized clinical trial. Fertil Steril. 2011 Mar 1;95(3):985-9.&#xD;
&#xD;
      van der Gaast, Eijkemans JB, de Boer EJ, Burger CW , van Leeuwen FE, Fauser BCJM , and&#xD;
      Macklon NS Optimum number of oocytes for a successful first IVF treatment cycle Reproductive&#xD;
      BioMedicine Online 2006 ; 13: 476-480&#xD;
&#xD;
      Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A.&#xD;
      Association between the number of eggs and live birth in IVF treatment: an analysis of 400&#xD;
      135 treatment cycles. Hum Reprod 2011; 26: 1768-1774&#xD;
&#xD;
      Chen QJ, Sun XX, Li L, Gao XH, Wu Y, Gemzell-Danielsson K, Cheng LN Effects of ovarian high&#xD;
      response on implantation and pregnancy outcome during controlled ovarian hyperstimulation&#xD;
      (with GnRH agonist and rFSH). Acta Obstet Gynecol Scand. 2007;86:849-54 Kyrou D.,&#xD;
      Popovic-Todorovic B., Fatemi H.M1, Bourgain C, Haentjens P., Van Landuyt L., and. Devroey P&#xD;
      Does the estradiol level on the day of human chorionic gonadotrophin administration have an&#xD;
      impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod 2009,&#xD;
      2902-2909,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cycle pregnancy rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>pregnancy rate per started cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate, multiple pregnancy rate, ongoing pregnancy rate ,live birth rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>implantation rate,multible pregnancy rate, abortion rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IVF</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone only arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol plus progesterone 100 mg IM injection</intervention_name>
    <description>estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET</description>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <other_name>estradiole valerate 2mg,</other_name>
    <other_name>Prontogest 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone IM of 100 mg</intervention_name>
    <description>Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer</description>
    <arm_group_label>Progesterone only arm</arm_group_label>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <other_name>prontogest 100 mg ampoles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  age&lt;40 years,&#xD;
&#xD;
          -  first ICSI cycle,&#xD;
&#xD;
          -  third day FSH&lt; 10 mIU/mL,&#xD;
&#xD;
          -  serum E2 level on day of hCG administration &lt;4,000 pg/mL,&#xD;
&#xD;
          -  number of ova obtained &gt;15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age 40 years or more,&#xD;
&#xD;
          -  basal FSH 10 mIU/mL or more ,&#xD;
&#xD;
          -  eggs retrieved 15 or less ,&#xD;
&#xD;
          -  E2 level on day of hCG administration 4000 or more pg/ mL or more,&#xD;
&#xD;
          -  repeat ICSI , need for PGD, presence of myoma , hydrosalpinx (unless disconnected)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mohamad E GHanem, MD</last_name>
    <phone>00201223366955</phone>
    <email>meghanem87@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura Integrated fertility center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura integrated fertility center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <phone>00201223366955</phone>
      <email>meghanem87@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008 Dec;90(6):2116-25. doi: 10.1016/j.fertnstert.2007.10.053. Epub 2008 Jan 7. Review.</citation>
    <PMID>18178194</PMID>
  </reference>
  <reference>
    <citation>Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.</citation>
    <PMID>21558332</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura Integrated Fertility Center</investigator_affiliation>
    <investigator_full_name>Mohamad Elsaid Ghanem</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>luteal support</keyword>
  <keyword>high responder</keyword>
  <keyword>ICSI</keyword>
  <keyword>ivf</keyword>
  <keyword>cycle outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

